> Legendary Duke neurosurgeon Dr. Allan Friedman operated on Senator Ted Kennedy's brain tumor, and there's already significant speculation that the lawmaker will undergo experimental therapy in a follow-up treatment. Report
> Medtronic's newly announced five-year growth targets include expectations for earnings to expand faster than sales and for smaller units to grow more quickly than the company's key heart-rhythm-device business. Release
> Twelve percent of patients who rush to the emergency room are there because of adverse effects from medications, according to a study being published today in the Canadian Medical Association Journal. Report
> Watson Pharmaceuticals got the FDA nod for its potassium-chloride extended-release capsules, the generic equivalent of KV Pharmaceutical's Micro-K Extencaps. Report
> Vertex Pharmaceuticals sold its rights to future royalties in the HIV treatment Lexiva and Agenerase under its license agreement with GlaxoSmithKline for $160 million in cash. Report
> Cephalon and its Cima Labs subsidiary have filed suit against Watson Pharmaceuticals for infringement of patents that cover methods of use for its Fentora pain medication; Cephalon says its patents don't expire until 2019. Report
> Mylan has acquired Merck KGaA's Central & Eastern Europe generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic; the deal stems from Mylan's buyout last year of Merck generics operations in several other regions. Report
> GlaxoSmithKline and Ligand Pharmaceuticals won a key endorsement for Promacta for the short-term treatment of people with chronic immune thrombocytopenic purpura, or ITP. Promacta report
> France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. Transgene report
> High school biology students are getting a chance to study drug development in school labs. Report
And Finally... Now here's an innovation: a T-shirt that, like your mother, constantly reminds you sit up straight. Report